ibandronate sodium

Phase 3Small molecule

SSWOG Cancer Research Network

ibandronate sodium is one of 33 small molecule programs targeting Bone pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bone PainActive, not recruiting

Breast CancerActive, not recruiting

Bone PainPhase 3

Active, not recruiting

Breast CancerPreclinical

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

ibandronate sodium

SSWOG Cancer Research Network

Phase 3

3 3

Adenocard

Astellas

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Acupan

YYonsei University

Preclinical

1 7

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 8

Conventional Chemotherapy

SShanghai Jiao Tong University School of Medicine

Preclinical

1 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer

Unknown status·WWales Cancer Trials Unit·Phase 3·NCT00326820·1,404 enrolled

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn·SSWOG Cancer Research Network··NCT00873808

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

Completed·SSWOG Cancer Research Network·Phase 3·NCT00127205·6,097 enrolled

Bone pain1 trial

Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain

Completed·CCancer Research UK·Phase 3·NCT00082927·580 enrolled

Unspecified1 trial

Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition

Completed·—·Phase 1·NCT01627886·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for ibandronate sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ibandronate sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ibandronate sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SWOG Cancer Research Network company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSWOG Cancer Research Network

ibandronate sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Bone pain1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News